TY1A-LR3 Antibody

What is TL1A and what is its role in the immune system?

TL1A (TNF-like ligand 1A, also known as TNFSF15) is a member of the TNF superfamily of proteins discovered approximately 20 years ago. It exists as both a type 2 transmembrane protein and in a soluble form (sTL1A). Under normal physiological conditions, TL1A is rarely expressed, but it becomes upregulated during tissue damage, necrosis, or inflammation. TL1A is primarily expressed by macrophages, dendritic cells, and endothelial cells when stimulated by TNF-α or other inflammatory signals .

TL1A exerts pleiotropic effects on immune cell proliferation, activation, and differentiation, particularly affecting helper T cells and regulatory T cells. When TL1A binds to its receptor DR3, it activates multiple intracellular signaling pathways that promote inflammation, cell survival, and cytokine production .

What are the primary receptors for TL1A and how do they function?

TL1A interacts with two main receptors: DR3 (death receptor 3), which is its cognate receptor, and DcR3, which serves as a decoy receptor. When TL1A binds to DR3, it triggers at least three different intracellular signaling pathways. The most significant pathway results in pro-inflammatory, survival-promoting effects through activation of Map kinases (p38, JNK, ERK) and NFkappaB .

The expression of full-length transmembrane DR3 is regulated differently between naive and activated T cells. In naive and resting T cells, DR3 expression is low or undetectable, whereas it becomes upregulated in activated T cells. This differential expression pattern helps explain why TL1A primarily affects activated and memory T cells rather than naive T cells .

How does TL1A affect different T cell subsets?

TL1A affects different T cell populations in distinct ways:

Research suggests that TL1A might preferentially act on Th17 cells due to their higher expression of DR3 compared to other T cell subsets. While in vitro studies have shown contradictory effects on Th17 differentiation, in vivo studies with TL1A transgenic mice indicate that TL1A-DR3 interaction positively regulates Th17 cell function .

What is the connection between TL1A and inflammatory bowel disease (IBD)?

In IBD patients, TL1A and DR3 are markedly expressed in inflamed mucosal areas. Studies have demonstrated that TL1A expression levels in tissue samples correlate with disease severity in IBD patients . The importance of this pathway in IBD pathogenesis is further supported by:

• TL1A overexpression in mouse models induces ileitis, colitis, and exacerbates fibrosis

• Within the innate immune system, TL1A, synergistically with IL-23, contributes to the proliferation of innate lymphoid cells (ILC3), which play an important role in mucosal immunity

• TL1A activates fibroblasts, leading to increased collagen production and fibrosis – a common, difficult-to-treat complication in IBD

• Polymorphisms of the TNFSF15 gene (which encodes TL1A) are associated with the pathogenesis of IBD and other autoimmune conditions

How do TL1A-targeted antibodies work as potential therapeutic agents?

Anti-TL1A antibodies work by preventing the interaction between TL1A and its receptor DR3, thereby inhibiting the downstream pro-inflammatory signaling cascades. These antibodies are designed to bind to TL1A with high specificity and affinity, neutralizing its biological activity .

By blocking this pathway, these antibodies aim to reduce inflammation, prevent tissue damage, and potentially reverse fibrosis in autoimmune conditions like IBD. The therapeutic approach relies on the central role that TL1A plays in orchestrating both innate and adaptive immune responses in inflamed tissues .

What is the current state of clinical testing for anti-TL1A antibodies in IBD?

Currently, there are three anti-TL1A antibodies in clinical testing, with the most advanced being RVT-3101 and PRA023. Phase 2 data has been released for both of these agents with promising results:

RVT-3101:

• Structure: Fully human IgG1 monoclonal anti-TL1A antibody

• Clinical trial: Phase 2a open-label study (Tuscany) in patients (n=50) with moderate-to-severely active ulcerative colitis (UC)

• Administration: Every other week intravenously and subcutaneously over 14 weeks

• Results: 38.2% of patients achieved endoscopic improvement (Mayo endoscopic sub-score = 0 or 1), significantly higher than the expected placebo rate of 6%. Endoscopic remission was achieved by 10% of patients

PRA023:

• Structure: IgG1-humanized monoclonal antibody with biochemical modifications making it less susceptible to internal degradation processes

• Clinical trials:

  • Artemis-UC study: Phase 2 placebo-controlled, randomized trial in patients (n=170) with moderate-to-severely active UC

  • Apollo-CD trial: Testing in patients (n=55) with moderate-to-severely active Crohn's Disease (CD)

• Administration: Four drug infusions over a 12-week period

• Results (Artemis-UC): 26.5% clinical remission (vs. 1.5% placebo), 36.8% endoscopic improvement (vs. 6% placebo)

• Results (Apollo-CD): Significant response rates even in heavily pretreated patients

Both agents have shown promising efficacy, particularly in patient populations who have previously failed other therapies. Current development also includes subcutaneous administration options and extended dosing intervals to improve patient convenience .

How effective are anti-TL1A antibodies in patients with prior biological therapy failure?

A particularly encouraging aspect of anti-TL1A antibody trials is their efficacy in patients who have failed previous biological therapies:

• In the RVT-3101 UC trials, up to 72% of patients were anti-TNF antibody experienced, yet the treatment still showed significant efficacy

• In the Apollo-CD trial of PRA023, 52.7% of patients had been treated with two or more biological agents before, with a mean disease duration of 10.3 years, and still showed response

While direct comparative data between anti-TL1A antibodies and other biological agents in TNF-refractory patients is limited, the preliminary results suggest that anti-TL1A antibodies may offer a new option for patients who have exhausted other treatments. This might be explained by TL1A's position upstream in the cytokine cascade relative to TNF-α .

What safety concerns exist with TL1A inhibition?

While no serious adverse events or new safety signals were reported in the induction periods of current clinical trials (12-14 weeks), several theoretical concerns warrant monitoring in long-term studies:

The safety profile currently appears acceptable, but the evidence base is limited by the short duration of existing clinical trials. Longer-term safety data will be crucial in establishing the complete risk profile of these agents .

What role does TL1A play in fibrosis development in IBD?

TL1A has been identified as a significant factor in the development of intestinal fibrosis, a common and challenging complication in IBD:

• TL1A directly activates fibroblasts, leading to increased collagen production and resulting fibrosis

• In mouse models, TL1A overexpression not only induces intestinal inflammation but also exacerbates fibrosis

• The pro-fibrotic effects of TL1A provide a rationale for targeting this pathway in IBD patients with fibrotic complications

This anti-fibrotic potential represents a unique advantage of TL1A inhibitors compared to some other biological therapies for IBD. If confirmed in long-term studies, this property could make TL1A inhibitors particularly valuable for patients with fibrostenotic disease phenotypes .

What is known about TL1A and DR3 expression patterns in different disease states?

TL1A and its receptors show distinctive expression patterns in various autoimmune and inflammatory conditions:

• In IBD: TL1A/DR3 are markedly expressed in inflamed mucosal areas, with expression levels correlating with disease severity

• In rheumatoid arthritis: A collagen-induced arthritis murine model showed reduction in bone erosions after TL1A inhibition

• In other autoimmune conditions: TL1A was found to be overexpressed in lupus erythematosus, ankylosing spondylitis, and primary biliary cirrhosis

• In skin disorders: Early data suggest a possible role of TL1A in atopic dermatitis and psoriasis inflammation

The expression patterns of TL1A and DR3 provide valuable biomarkers for disease activity and potential predictors of treatment response. This has led to the development of companion diagnostics in clinical trials to identify patients with genetic predisposition to express higher amounts of TL1A, who may have a higher probability of response to anti-TL1A agents .

How do companion diagnostics function in TL1A inhibitor clinical trials?

Companion diagnostics have been incorporated into anti-TL1A antibody clinical trials to identify patients more likely to respond to treatment:

• These diagnostics aim to identify patients who are genetically predisposed to express higher amounts of TL1A

• In the Artemis-UC study of PRA023, a companion diagnostic was used to screen for patients with this genetic profile

• The hypothesis is that patients with higher TL1A expression will have a higher probability of response to TL1A inhibition

What are the differences between the mechanisms of various anti-TL1A antibodies in development?

While all anti-TL1A antibodies target the same pathway, there are notable differences in their structure and mechanisms:

RVT-3101:

• Structure: Fully human IgG1 monoclonal anti-TL1A antibody

• Administration: Being tested for subcutaneous application

• Development focus: Convenience of administration

PRA023:

• Structure: IgG1-humanized monoclonal antibody with biochemical modifications making it less susceptible to internal degradation

• Proposed dosing: Monthly interval

• Theoretical advantage: Enhanced stability may translate to increased efficacy

These structural and pharmacokinetic differences may impact several aspects of treatment:

• Immunogenicity and development of anti-drug antibodies

• Duration of effect and dosing intervals

• Route of administration

• Penetration into inflamed tissues

Further head-to-head studies would be needed to determine if these differences translate to meaningful clinical distinctions in efficacy or safety profiles .

How do polymorphisms of the TNFSF15 gene affect autoimmune disease susceptibility?

The TNFSF15 gene, which encodes TL1A, has been associated with several autoimmune conditions:

• Polymorphisms of TNFSF15 are associated with the pathogenesis of:

  • Irritable bowel syndrome

  • Inflammatory bowel disease

  • Ankylosing spondylitis

  • Primary biliary cirrhosis

  • Leprosy

These genetic variations may influence TL1A expression levels, protein structure, or function, potentially explaining differences in disease susceptibility, severity, and response to treatment. Identifying these polymorphisms could help in patient stratification for clinical trials and eventually in personalized medicine approaches for anti-TL1A therapies .